Ascendis Pharma Gains FDA Approval for Yuviwel First Weekly Achondroplasia Therapy
Ascendis Pharma won FDA approval for Yuviwel, its first once-weekly treatment for children aged two and older with achondroplasia, earning a Rare Pediatric Disease Priority Review Voucher. Yuviwel will be available to U.S. prescribing physicians in early Q2 2026, bolstering the company’s rare pediatric portfolio.
1. FDA Approval of Yuviwel
The FDA has approved Yuviwel (navepegritide) as the first and only once-weekly prodrug treatment designed to increase linear growth in children aged two years and older with achondroplasia under a Rare Pediatric Disease Priority Review Voucher.
2. Pivotal Trial Results
Phase III data from three randomized trials, including the week-52 ApproaCH study, demonstrated significantly higher annualized growth velocity versus placebo, improved limb alignment and body proportionality, and a safety profile comparable to placebo.
3. Commercial Launch Plans
Ascendis Pharma plans to make Yuviwel available through U.S. prescribing physicians in early Q2 2026 and will leverage the Priority Review Voucher to potentially expedite future drug submissions.
4. Stock Reaction and Technical Outlook
In premarket trading, shares rose on the approval news; the stock sits 0.42% below its 20-day SMA and 2.45% above its 100-day SMA, with RSI at a neutral 50.00 and MACD at 0.15 below its 0.22 signal line, indicating mixed momentum.